Story perspectives

FDA Drug Chief Resigns Amid Misconduct Allegations, Lawsuit

11/5/2025

Summary

Story summary

Dr. George Tidmarsh resigned as head of the FDA's drug division amid allegations of misconduct and a lawsuit from Aurinia Pharmaceuticals.
Tidmarsh was placed on administrative leave after concerns about his personal conduct were raised.
Tidmarsh criticized a new fast-track drug approval process for undermining scientific rigor.
Aurinia's lawsuit alleges Tidmarsh defamed its lupus drug and pursued a personal vendetta against Aurinia's board chair Kevin Tang.

History

Historical Context

The FDA's Accelerated Approval Program, initiated in 1992, aimed to expedite drug approvals for serious conditions, partly in response to criticisms from AIDS activists in the late 1980s. This program led to a 30% increase in drug sales for companies like Pfizer. However, Dr. George Tidmarsh's resignation amid misconduct allegations highlights ongoing concerns about the integrity of drug approval processes and may prompt further scrutiny of FDA practices.

1 of 2

Story summary

Dr. George Tidmarsh resigned as head of the FDA's drug division amid allegations of misconduct and a lawsuit from Aurinia Pharmaceuticals.
Tidmarsh was placed on administrative leave after concerns about his personal conduct were raised.
Tidmarsh criticized a new fast-track drug approval process for undermining scientific rigor.
Aurinia's lawsuit alleges Tidmarsh defamed its lupus drug and pursued a personal vendetta against Aurinia's board chair Kevin Tang.

1 / 2